<DOC>
	<DOCNO>NCT00006081</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine bryostatin 1 paclitaxel treat patient unresectable locally advanced metastatic stomach cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Unresectable Locally Advanced Metastatic Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction treat bryostatin 1 paclitaxel . - Determine qualitative quantitative toxicity reversibility toxicity regimen patient . OUTLINE : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 bryostatin 1 IV 1 hour day 2 , 9 , 16 . Treatment continue every 4 week least 2 course absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 4 course achieve CR . Patients follow death . PROJECTED ACCRUAL : A total 18-35 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients histologic proof adenocarcinoma stomach gastroesophageal junction eligible . 2 . Patients must either metastatic unresectable localregional cancer 3 . Patients must measurable disease , define lesion accurately measure least one dimension ( long diameter record ) great equal 20 mm conventional technique great equal 10 mm spiral CT scan . 4 . Patients may receive prior chemotherapy immunotherapy regimen except adjuvant therapy end least 6 month prior registration study . 5 . Prior limited radiation therapy permit . Prior radiotherapy must include major bone marrow contain area ( pelvis , lumbar spine ) , contain single evaluable lesion radiation field . A recovery period least 4 week completion radiotherapy require prior enrollment . Patients receive chemotherapy use radiosensitizer eligible except chemoradiotherapy administer adjuvant setting ( see 4.4 ) . 6 . Patients must life expectancy least 12 week . 7 . Patients must performance status less equal 2 ( Zubrod scale ) great equal 60 % ( Karnofsky scale ) ( see appendix B ) . 8 . Patients must give write informed consent . 9 . Acceptable liver , renal , marrow function 10 . Patients must least 18 year old . 11 . Patients must recover recent surgery . One week must elapse time minor surgery 3 week major surgery . 12 . This clinical trial design person shall ground race , color , gender national origin exclude participation deny benefit , otherwise subject discrimination study . 1 . Patients may receive concurrent chemotherapy , immunotherapy , radiotherapy . 2 . Patients brain metastasis eligible . 3 . Patients NYHA Class III IV heart disease eligible ( see Appendix F ) well patient history angina , myocardial infarction , congestive heart failure within six month . 4 . Pregnant lactate woman paclitaxel bryostatin1 , like anticancer agent , may harmful develop fetus nursing newborn infant . All woman childbearing potential must negative pregnancy test prior entry study . All patient childbearing potential must advise importance avoid pregnancy use appropriate method contraception participate investigational trial . 5 . Patients serious intercurrent infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy , ineligible . 6 . Patients psychiatric disorder render incapable comply wiht requirement protocol ineligible . 7 . Patients serum calcium great &gt; 12 mg/dl symptomatic hypercalcemia treatment ineligible . 8 . Patients bone metastasis . 9 . Patients concurrent active malignancy nonmelanoma skin cancer carcinomainsitu cervix . Patients previous malignancy without evidence great equal 5 year allow enter trial . 10 . Patients wit bleed diathesis require anticoagulation exclude . 11 . Patients nonmeasurable disease , define lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>